Quince Therapeutics
269 E. Grand Avenue
South San Francisco
CA
94080
United States
Tel: 6508674547
Website: http://www.cortexyme.com/
Email: careers@cortexyme.com
127 articles about Quince Therapeutics
-
Cortexyme’s Atuzaginstat Slowed Cognitive Decline in Participants With Alzheimer’s Disease and P. Gingivalis Infection in Phase 2/3 GAIN Trial: Additional Top-line Data Presented at CTAD 2021
11/11/2021
Cortexyme, Inc. (Nasdaq: CRTX) will present additional data from its Phase 2/3 GAIN Trial at the 14th Clinical Trials on Alzheimer's Disease Conference (CTAD 2021) as a part of the meeting’s Late-Breaking Readout Roundtable program today, Thursday, November 11, 2021.
-
Cortexyme to Present Additional Top-line GAIN Trial Results and Analysis at CTAD 2021 on November 11th
11/4/2021
Cortexyme to Present Additional Top-line GAIN Trial Results and Analysis at CTAD 2021 on November 11th
-
Cortexyme Reports GAIN Trial Data Demonstrated Relationship Between Reduction of P. gingivalis Infection and Slowing of Alzheimer’s Disease Progression
10/26/2021
Cortexyme, Inc. (Nasdaq: CRTX) today reported top-line results from its Phase 2/3 GAIN Trial, a double-blind, placebo-controlled study evaluating the efficacy of atuzaginstat (COR388), an investigational orally administered small-molecule that targets gingipain proteases from the bacterium Porphyromonas gingivalis (P. gingivalis).
-
Cortexyme to Present Results from the GAIN Trial: A Phase 2/3 Study of Atuzaginstat in Mild to Moderate Alzheimer’s Disease at CTAD 2021
9/27/2021
Cortexyme, Inc. today announced that it will participate at the upcoming 14th Clinical Trials on Alzheimer's Disease (CTAD 2021) conference scheduled for November 9-12, 2021, in Boston, Massachusetts, as well as virtually.
-
Cortexyme Expands Proprietary Development Pipeline with Initiation of Phase 1 Clinical Trial of COR588
9/8/2021
Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer’s disease with top-line data expected by mid-November 2021 and a growing pipeline of therapeutics for degenerative diseases, today announced that the first cohort of healthy participants have been dosed in the Phase 1 clinical trial of its new drug candidate, COR588.
-
Cortexyme to Present at H.C. Wainwright 23rd Annual Global Investment Conference on September 13th
9/7/2021
Cortexyme to Present at H.C. Wainwright 23rd Annual Global Investment Conference on September 13th
-
The Annual Biomarkers for Alzheimer’s Disease Summit is running from August 25-26. Here’s a look at some of the top stories from day one.
-
Cortexyme Presents New Data Demonstrating Evidence of P. Gingivalis Infection of the Central Nervous System in Alzheimer’s Disease at Annual Biomarkers for Alzheimer’s Disease Summit
8/25/2021
Cortexyme Presents New Data Demonstrating Evidence of P. Gingivalis Infection of the Central Nervous System in Alzheimer’s Disease at Annual Biomarkers for Alzheimer’s Disease Summit
-
Cortexyme to Present at Annual Biomarkers for Alzheimer’s Disease Summit
8/18/2021
Cortexyme, Inc. will participate as a featured speaker covering its pivotal Phase 2/3 GAIN Trial
-
Cortexyme Provides Business Update and Reports Second Quarter 2021 Results
8/9/2021
Cortexyme, Inc. today provided an update on expected clinical top-line data and reported second quarter 2021 financial results.
-
Cortexyme to Present at Canaccord Genuity' s 41st Annual Growth Conference on August 11th
8/4/2021
Cortexyme to Present at Canaccord Genuity' s 41 st Annual Growth Conference on August 11 th
-
Cortexyme Presents Data Linking P. Gingivalis to Elevated Levels of Phospho-tau217 Reinforcing Evidence of Pathogen as Causative Agent of Alzheimer’s Disease at AAIC 2021
7/26/2021
Cortexyme Presents Data Linking P. Gingivalis to Elevated Levels of Phospho-tau217 Reinforcing Evidence of Pathogen as Causative Agent of Alzheimer’s Disease at AAIC 2021
-
Today is the first day of the Alzheimer’s Association International Conference 2021 (AAIC), behind held both virtually and in person in Denver, Colorado. Here’s a look at some of today’s stories.
-
Cortexyme Announces Lead 3CLpro Inhibitor for the Treatment of Coronavirus Infection
7/23/2021
Cortexyme, Inc. announced the selection of a lead 3CLpro inhibitor (COR803) for treatment of coronavirus infections, including COVID-19 disease, caused by SARS-CoV-2 infection.
-
With COVID-19 resurging in the U.S., particularly in states with the lowest vaccination rates, additional news and research about the vaccines and the virus is coming out. Here’s a look.
-
Cortexyme to Present New Data at AAIC 2021
7/22/2021
Cortexyme, Inc. announced that it will present two poster presentations at the Alzheimer's Association International Conference® 2021 (AAIC®) taking place July 26-30, 2021, in Denver, Colorado, as well as virtually.
-
Cortexyme Presents New Data Demonstrating Atuzaginstat Disrupts Biofilms and is Efficacious in Preclinical Models of Periodontal Disease at IADR 2021
7/21/2021
Cortexyme Presents New Data Demonstrating Atuzaginstat Disrupts Biofilms and is Efficacious in Preclinical Models of Periodontal Disease at IADR 2021
-
Cortexyme to Host Symposium at AAIC 2021
7/19/2021
Cortexyme, Inc. announced that it will host a corporate sponsored symposium and dinner held in conjunction with the Alzheimer's Association International Conference® 2021 (AAIC®) taking place July 26-30, 2021, in Denver, Colorado, as well as virtually.
-
Cortexyme to Host Two-Part Key Opinion Leader Webinar Series on Atuzaginstat
7/8/2021
Part 1 to be held Friday July 23 at 10:00 a.m. ET: Innovation in Periodontal Disease – A Major Unmet Medical Need Part 2 to be held Friday July 30 at 10:00 a.m. ET: Innovation in Alzheimer's Disease – Getting to the Root Cause of Neurodegeneration
-
Cortexyme Presents Updated Baseline Data from Complete Set of Participants Enrolled in Pivotal GAIN Trial at ASCP 2021 Annual Meeting
6/1/2021
Cortexyme Presents Updated Baseline Data from Complete Set of Participants Enrolled in Pivotal GAIN Trial at ASCP 2021 Annual Meeting Baseline demographic and biomarker data reinforce appropriate patient population enrolled ahead of top-line data expected in fourth quarter 2021